MyFinsight
Home
Blog
About
Contact
Proceeds from borrowings
under the revolving...
$250,000K
Proceeds from exercise of
stock options and...
$241K
Net cash provided by
financing activities
$241K
Canceled cashflow
$250,000K
Decrease in cash, cash
equivalents and restricted...
-$336,832K
Canceled cashflow
$241K
Net income (loss)
$330,959K
Decrease in
manufacturing-related deposits and...
-$43,487K
Stock-based compensation
$29,399K
Depreciation and
amortization
$10,594K
Non-cash interest
expense
$9,612K
Decrease (increase) in
accounts receivable
-$3,416K
Reduction in the carrying
amounts of the right of...
$3,110K
Loss on strategic
investments
-$1,712K
Maturity and sales of
available-for-sale securities
$38,888K
Repayments of borrowings
under the revolving...
$250,000K
Net cash used in
operating activities
-$202,683K
Net cash provided by
investing activities
-$134,390K
Canceled cashflow
$432,289K
Canceled cashflow
$38,888K
Decrease in deferred
revenue
-$274,916K
Purchase of
available-for-sale securities
$170,197K
Decrease in accounts
payable
-$210,465K
Increase in inventory
$69,756K
(decrease) increase in
accrued expenses
-$60,026K
Increase in other assets
$14,547K
(decrease) increase in
lease liabilities and...
-$3,444K
Other
$1,288K
Accretion of investment
discount, net
-$530K
Purchase of property and
equipment
$2,081K
Purchase of intangible
assets
$1,000K
Back
Back
Cash Flow
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)
source: myfinsight.com